Message from the Dean
Greetings from the Dean of the School of Medicine/Graduate School of Medicine
On behalf of the Nagoya University School of Medicine and Graduate School of Medicine, I am honored to have this opportunity to say a few words of greeting.
The Nagoya University School of Medicine was originally founded in 1871 (Meiji year 4) by the Nagoya feudal clan as a temporary hospital and temporary medical school. With a history and traditions stretching back 140 years, it is one of the oldest medical schools in Japan. In 1939 the University became the seventh Imperial University in Japan, with faculties of medicine and science and engineering. In 1949, after World War II, it was restarted as Nagoya University under a new education system.
In 1997 the Department of Health Sciences was established; the School of Medicine thus came to comprise two faculties, Medicine and Health Sciences. Then, in 2000, Nagoya University completed organizational strengthening of its graduate schools and, as a graduate university, it restructured the Graduate School of Medicine by reorganizing the basic and clinical medicines into four research fields: Integrated Molecular Medicine, Cell Information Medicine, Function Construction Medicine and Health & Community Medicine. In this school year, these four programs have been merged into one program named the Program in Integrated Medicine, in which three divisions, the Division of Basic Medicine, the Division of Clinical Medicine, and the Division of Clinical Pharmacology, have been established. For the Division of Clinical Pharmacology, we have just launched two new disciplines, Biostatistics and Toxicogenomics, to enhance drug discovery and clinical medicine research. Additionally, in the Division of Clinical Pharmacology, we are offering some new joint sub-divisions in order to strengthen the development of individuals with potential capability in drug discovery and those with the ability to accelerate clinical trials, because this is an area in which Japan lags behind other countries. These sub-divisions include one developed under an industry-academia collaboration in cooperation with pharmaceutical companies including Novartis Pharmaceuticals Japan and Astellas Pharma Inc., one jointly organized with Meijo University Graduate School of Pharmacy, and one with the Institute of Statistical Mathematics and the Pharmaceuticals and Medical Devices Agency.
Simultaneously with the reorganization of the Graduate School of Medicine as described above, we are improving the facilities that support the basis of our education and research, as a result of which the construction of the Graduate School of Medicine's research building No. 3 will be completed during this school year. This building will include an anatomy training room for students, a histological/pathological training room, a radioisotope center, and a common-use equipment center. The building will also provide space for various project-based studies, including those conducted by endowed chairs and by industry-academia collaborative sub-divisions. Biostatistics and Toxicogenomics, the new disciplines which will be established in the Division of Clinical Pharmacology as mentioned earlier, will also be housed in building No. 3, thus improving our education and study environment.
As one of the major missions of the Graduate School of Medicine this year, we intend to accelerate the internationalization of the institution at the research level. Following the symposium organized with the Medical University of Vienna in January 2013, we held another symposium at the University of Adelaide in Australia in May. These were attended by many research scientists from the Graduate School of Medicine, thus deepening our mutual relationships with the two universities. Since international joint studies will increasingly be required in the future, we intend to organize similar symposiums on a regular basis.
We aim to have a School of Medicine and Graduate School full of vitality, and intend to put all possible effort into achieving this. We appreciate your advice and guidance.
Masahide TAKAHASHI, MD, PhD
Dean of the School of Medicine and Graduate School of Medicine,
Fields of Specialization
1. Experimental Pathology
2. Tumor Biology
3. Molecular Neurobiology
1. Molecular mechanisms of cancer invasion and metastasis
2. Mechanisms of anticancer drug resistance
3. Development of the nervous system and the molecular pathogenesis of neuropsychiatric disorders
1. Ishida-Takagishi, M., Enomoto, A., Asai, N., Ushida, K., Watanabe, T., Hasimoto, T., Kato, T., Weng, L., Matsumoto, S., Asai, M.,
Murakumo, y., Kaibuchi, K., Kikuchi, A. and Takahashi, M.
The Dvl-associated protein Daple controls the non-canonical Wnt/Rac pathway and cell motility. Nature Commun. (2012)
2. Enomoto, A., Asai, N., Namba, T., Wang, Y., Kato, T., Tanaka, M., Tatsumi, H., Taya, S., Tsuboi, D., Kuroda, K., Kaneko, N., Sawamoto, K.,
Miyamoto, R., Jijiwa, M., Murakumo, Y., Sokabe, M., Seki, T., Kaibuchi, K. and Takahashi, M.
Roles of Disrupted-in-Schizophrenia 1-interacting protein Girdin in postnatal development of the dentate gyrus. Neuron 63: 774-787 (2009).
3. Kitamura, T., Asai, N., Enomoto, A., Maeda, K., Kato, T., Ishida, M., Jiang, P., Watanabe, T., Usukura, J., Kondo, T., Costantini,
F., Murohara, T. and Takahashi, M.
Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nature Cell Biol., 10:329-337 (2008).
4. Enomoto, A., Murakami, H., Asai, N., Morone, N., Watanabe, T., Kawai, K., Murakumo, Y., Usukura, J., Kaibuchi, K., and Takahashi, M.
Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev. Cell 9: 389-402 (2005).
5. Klein, R.D., Sherman, D., Ho, W.-H., Stone, D., Bennett, G. L., Moffat, B., Vandlen, R., Simmons, L., Gu, Q., Hongo, J.-A., Devaux, B.,
Poulsen, K., Armanini, M., Nozaki, C., Asai, N., Goddard, A., Phillips, H., Henderson, C. E., Takahashi, M. and Rosenthal, A.
A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature 387: 717-721 (1997).
6. Asai, N., Iwashita, T., Matsuyama, M. and Takahashi, M.
Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell. Biol. 15: 1613-1619 (1995).
7. Takahashi, M., Ritz, J. and Cooper, G.M.
Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42: 581-588 (1985).